Despite the substantial difficulties associated with orphan drug trial recruitment, this segment of the drug development market is booming.  By 2020, orphan drug sales are expected to make up 19% of prescription drug sales, excluding generics.  In ISR’s 

Orphan Drug Market Dynamics and Patient Recruitment Best Practices 

report, ISR provides an overview of the orphan drug development market as well as how to best drive patient recruitment in an area of drug development in which drug developers do not want to be left behind.  